Overview of the PTAC Proposal Submission Process

Jeffrey Bailet, PTAC Chair
Elizabeth Mitchell, PTAC Vice Chair

December 16, 2016
PTAC’s Statutory Charge

• The Physician-Focused Payment Model Technical Advisory Committee (PTAC) was created under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)

• The purpose of PTAC is to:
  • Review proposals submitted by individuals and stakeholder entities for physician-focused payment models (PFPMs); and
  • Provide comments and recommendations to the Secretary of Health and Human Services (the Secretary) regarding whether each proposal meets criteria for PFPMs established by the Secretary

• By statute, the Secretary of HHS must review the comments and recommendations of PTAC and post a detailed response on the website of the Centers for Medicare & Medicaid Services (CMS)
PTAC: Goals and Process

PFPM = Physician-Focused Payment Model

Goal: to encourage new APM options for Medicare clinicians

Submission of model proposals by stakeholders → Technical Advisory Committee

11 GAO appointed care delivery experts that review proposals, submit recommendations to the HHS Secretary

Secretary comments on CMS website, CMS considers testing proposed models
Criteria for Evaluating Models

- Scope of Proposed PFPM (high priority)
- Quality and Cost (high priority)
- Payment Methodology (high priority)
- Value over Volume
- Flexibility
- Ability to be Evaluated
- Integration and Care Coordination
- Patient Choice
- Patient Safety
- Health Information Technology
What is a Physician-Focused Payment Model?

• A physician-focused payment model (PFPM) is an Alternative Payment Model:
  • In which Medicare is a payer;
  • In which eligible clinicians that are eligible professionals as defined in section 1848(k)(3)(B) of the Act are participants and play a core role in implementing the APM’s payment methodology, and
  • Which targets the quality and costs of services that eligible professionals participating in the Alternative Payment Model provide, order, or can significantly influence.
Characteristics of PFPMs Likely to be Recommended by PTAC

- PFPMs that require eligible professionals receiving the payment to take accountability for (1) reducing spending without reducing the quality care, (2) improving the quality of care without increasing spending, or (3) improving the quality of care and reducing spending.
- PFPMs that directly affect the method and/or amount of payments for one or more services delivered, ordered, managed, or coordinated by one or more types of eligible professionals.
- Unlikely to recommend a proposed PFPM if the only change it makes is to give an eligible professional the ability to bill for a single type of service that is not currently eligible for payment under the Medicare Physician Fee Schedule.
- Will consider proposals for PFPMs that would need to be implemented through entities other than practices or groups consisting of one or more eligible professionals.
- PFPMs that change the method of payment for eligible professionals if the payment model also requires those receiving the payment to take accountability for controlling the costs and quality of care for the patients affected.
Stakeholder Model Submissions

• PTAC began receiving letters of intent (LOIs) on October 1, 2016
  – LOIs must be submitted at least 30 days prior to full proposals
• Full proposals have been accepted since December 1, 2016
• LOIs and proposal submissions may be sent to PTAC through ScholarOne
  https://mc04.manuscriptcentral.com/ptac
Opportunities for Public Participation

• All public meetings will be publicized on the Federal Register and announced through PTAC’s listserv
• Public comments are invited at all public meetings and on all key documents
• We invite you to visit PTAC’s website, https://aspe.hhs.gov/ptac-physician-focused-payment-model-technical-advisory-committee
• Email us at PTAC@hhs.gov with questions and join our listserv (https://list.nih.gov/cgi-bin/wa.exe?A0=PTAC) to stay updated on all PTAC activities
• Questions?
Physician-Focused Payment Model
Technical Advisory Committee

PTAC Process for Reviewing and Evaluating Proposed Physician-Focused Payment Models
&
Discussion of Public Comments

Bruce Steinwald, PTAC Member
Kavita Patel, PTAC Member

December 16, 2016
Development of PTAC Evaluation Process

  

- Document describes proposed processes to be used by PTAC to review and evaluate Physician-Focused Payment Models (PFPMs) submitted by stakeholders as provided for by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).

- Document also describes how PTAC will develop comments and recommendations for the Secretary of Health and Human Services for each submitted PFPM.

- Written public comments were due December 9, 2016
PTAC Aiming For a 16-Week Process

- Letter of Intent
- At least 30 days before proposal submission
- 16 weeks for PTAC review
- PTAC Proposal Review & Recommendation
- Not Recommended

Recommend for:
- Limited-scale testing of the proposed payment model;
- Implementation of the proposed payment model; or
- Implementation of the proposed payment model as a high priority
Composition of Preliminary Review Team:
- Only members of PTAC
- At least one physician
- No one with a conflict of interest
- One individual as lead reviewer

Support for Preliminary Review Team:
- ASPE Staff
- ASPE Contractors
  - Additional subject matter experts if needed
  - No conflicts of interest
  - Publicly identified

Factors Affecting Schedule for PTAC Deliberation Meeting
- Feasibility of submitter to attend
- Volume of applications
PTAC Proposal Review and Recommendation Process

- **Proposal Submitted**
- **Proposal reviewed for completeness**
- **Complete proposal assigned to Preliminary Review Team (PRT) and posted for public comment**
- **PRT identifies any additional information needed:**
  - from submitter
  - clinical consultation
  - data & analyses
  - other info
- **Any requests for additional information sent to relevant party**
- **PRT reviews proposal, additional information, and public comments, and discusses ratings and recommendation**
- **PRT drafts report on extent to which proposal meets criteria and draft recommendation**
- **Full PTAC deliberates and votes on recommendation at public meeting**
- **PTAC sends report with recommendation to Secretary and submitter**

**Public Report**
No Deadlines on When Proposals Can Be Submitted; Rolling Reviews & Decisions

12/1/16  1/1/17  2/1/17  3/1/17  4/1/17  5/1/17  6/1/17  7/1/17  8/1/17

PTAC Proposal Review & Recommendation

PTAC Proposal Review & Recommendation

PTAC Proposal Review & Recommendation

PTAC Proposal Review & Recommendation
Questions on Evaluation Document

• Will the PTAC review all PRT-reviewed proposals or only those that “meets the criterion” or “meets the criterion and deserves priority consideration?”

• Can a proposal have a “0” score in one or more criterion, for example in any or all of the “high priority criterion” and still receive a “meets” or “meets the criterion and deserved priority consideration” recommendation?

• The draft makes mention of “contractors.” What role/s will these contractors serve and will their expertise be available to organizations submitting and/or revising their PTAC proposals?

• What is the process in instances when the PRT does not reach a consensus?
Questions on Evaluation Document

• The process says, “The PRT and ASPE staff and contractors will arrange any needed analyses so as to minimize the extra time required to review the proposal.” Will the submitter of the proposal be billed? Will PTAC absorb the costs of the needed analyses?

• Will PTAC have the discretionary authority to approve a plan for CMS review even if it does not meet all ten criteria but has an adequate explanation as to why it does not meet a particular criterion and perhaps proposes a possible substitute criterion?

• Will the submitter of the proposed model be provided with specific information on when the public meeting will be held or will that information only be available by monitoring the website?

• Will there be any opportunity to appeal, or should one just submit a new proposal once any defects have been cleared?

• Once a proposed model has been approved, can it then be implemented by any party? Would anyone with questions be told to contact the submitter or will questions be resolved by the PTAC?
Other comments or questions today?
USING AN EPISODE-BASED PAYMENT MODEL TO IMPROVE ONCOLOGY CARE

Center for Medicare & Medicaid Innovation
OCM Overview
OCM TIMELINE

Oncology Care Model Timeline

February 2015
• U.S. Department of Health and Human Services announces new initiative to encourage better oncology care

April 2015 & May 2015
• Letters of intent due from payers (April 2015) and providers (May 2015)

June 2015
• Applications due to the Centers for Medicare & Medicaid Services

April 2016
• Providers and payers notified of acceptance April 2016

July 2016
• OCM launched with almost 200 participating physician practices and 16 payers
MODEL OVERVIEW

Five-year, episode-based payment model (July 1, 2016-June 30, 2021)

• Payment model targets chemotherapy and related care during a 6-month period following the initiation of chemotherapy treatment

Emphasizes practice transformation

• Physician practices engage in practice transformation to deliver high quality care at lower cost

Nation-wide scope with three overarching goals

• Improve health outcomes for patients with cancer
• Improve quality of cancer care
• Reduce spending while achieving similar or greater quality for cancer treatment

Multi-payer model
PRACTICE REDESIGN ACTIVITIES

1) Provide Enhanced Services

Provide OCM Beneficiaries with 24/7 access to an appropriate clinician who has real-time access to the Practice’s medical records

Provide the core functions of patient navigation to OCM Beneficiaries

Document a care plan for each OCM Beneficiary that contains the 13 components in the Institute of Medicine Care Management Plan

Treat OCM Beneficiaries with therapies that are consistent with nationally recognized clinical guidelines
2) **Use certified electronic health record technology (CEHRT)**

OCM Practices must use CEHRT in a manner sufficient to meet the requirements of an “eligible alternative payment entity” under the MACRA rule implementing the Quality Payment Program.

3) **Utilize data for continuous quality improvement**

Practices must collect and report clinical and quality data to the Innovation Center. In addition, the Innovation Center will provide participating practices with feedback reports for practices to use to continuously improve OCM patient care management.
IOM CARE PLAN

- Patient name, DOB, medication list, allergies
- Diagnosis (stage, biomarkers, histology)
- Prognosis
- Treatment goals
- Treatment plan and duration
- Expected response to treatment
- Treatment benefits and harms
- Patient’s anticipated experience with treatment
- Who takes responsibility for aspects of patient’s care
- Advanced care plans
- Estimated total and out of pocket costs
- Plan for addressing psychosocial needs
- Survivorship plan
OCM-FFS BENEFICIARY POPULATION

Medicare beneficiaries who meet each of the following criteria for the entire 6-month episode are included in OCM-FFS:

• Enrolled in Medicare Parts A and B;
• Does not receive the Medicare End Stage Renal Disease (ESRD) benefit;
• Medicare as his or her primary payer;
• Not covered under Medicare Advantage or any other group health program;
• Received an included chemotherapy treatment for cancer; and
• Has at least one Evaluation & Management (E&M) visit with an included cancer diagnosis during the 6 months of the episode.
OCM PRACTICES

Nearly 200 oncology practices are participating in OCM.

OCM Practices:

- Medicare-enrolled physician groups identified by a single Taxpayer Identification Number (TIN)
- Composed of one or more physicians who treat Medicare beneficiaries diagnosed with cancer
- Cover urban, suburban and rural areas
- Range in size from solo oncologists to large practices with hundreds of providers
- Individual practitioners identified by NPI/TIN combination

- OCM excludes entities that are paid based on alternative payment methodologies, including PPS exempt cancer hospitals, Critical Access Hospitals, Federally Qualified Health Centers, Rural Health Clinics, and both Maryland hospitals and Maryland physician practices
OCM PAYERS

- 16 commercial insurers are supporting OCM practices in their practice transformation efforts; payers include regional and national organizations

- The goal of multi-payer participation is to provide aligned financial support and quality measurement across a practice’s patient population, in order to facilitate whole practice change

- CMS and the OCM payers will convene regularly throughout the model to share lessons learned on engaging in alternative payment model work that supports oncology practice transformation
Episode Definition
Types of Cancer
- OCM includes nearly all cancer types

Episode initiation
- Episodes initiate when a beneficiary starts chemotherapy
- The Innovation Center has devised a list of chemotherapy drugs that trigger OCM episodes, including endocrine therapies but excluding topical formulations of drugs

Included services
- All Medicare A and B services that Medicare FFS beneficiaries receive during an episode
- Certain Part D expenditures are also be included

Episode duration
- OCM episodes extend six months after a beneficiary’s chemotherapy initiation
- Beneficiaries may initiate multiple episodes during the five-year model performance period
DRUG LIST
(INITIATORS OF EPISODE IN COMBINATION WITH QUALIFYING ICD 10 CODE)

• Include the **vast majority** of chemotherapy agents

• Does not include radiation sensitizing agents, supportive care medications or growth factors

• May not include drugs that are often used for non malignant conditions and generally used in combination with other chemotherapy drugs (prednisone)

• May not include drugs that are infrequently used in cancer but frequently used for non-malignant conditions (hydroxyurea, interferon alpha 2B)
Each episode will be attributed to the practice that provided the most E&M visits with a cancer diagnosis during the episode (“plurality approach”)

OCM practices are defined by the TIN used to bill for professional services

OCM practitioners are defined by NPI. The TIN/NPI combination is used for purposes of identification
Quality
QUALITY MEASURES – OVERVIEW

Quality measures were selected for OCM across four of the National Quality Strategy (NQS) Domains, including:

- Communication and Care Coordination
- Person and Caregiver-Centered Experience and Outcomes
- Clinical Quality of Care
- Patient Safety

These measures were selected after extensive literature review, review by a Technical Expert Panel, and consideration of alignment with other quality reporting efforts.

To the extent possible, OCM utilizes existing data such as claims or data collected within other CMS programs in an effort to reduce burden on OCM Participants.
CLAIMS-BASED QUALITY MEASURES

- Claims-based measures are pay-for-performance beginning in performance period one.
- Performance on claims-based measures are scored utilizing comparisons to national benchmarks.

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>OCM Measure Number</th>
<th>NQS Domain</th>
<th>Reporting Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk-adjusted proportion of patients with all-cause hospital admissions within the 6-month episode</td>
<td>OCM-1</td>
<td>Communication and Care Coordination</td>
<td>Calculated by CMS using administrative data</td>
</tr>
<tr>
<td>Risk-adjusted proportion of patients with all-cause ED visits that did not result in a hospital admission within the 6-month episode</td>
<td>OCM-2</td>
<td>Communication and Care Coordination</td>
<td>Calculated by CMS using administrative data</td>
</tr>
<tr>
<td>Proportion of patients who died who were admitted to hospice for 3 days or more</td>
<td>OCM-3</td>
<td>Communication and Care Coordination</td>
<td>Calculated by CMS using administrative data</td>
</tr>
</tbody>
</table>
PATIENT-REPORTED EXPERIENCE MEASURE

- The Patient-reported experience of care measure performance-based payment will be based on items recommended in the first Consumer Assessment of Healthcare Providers and Systems (CAHPS) for Cancer Care field test.

- Performance rates will be calculated using aggregated composite-level scores to create a summary “patient experience of care” score.

- The survey will be administered and collected by the OCM Evaluation contractor. OCM Participants are not required to administer or contract with a survey vendor to collect survey data.

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>OCM Measure Number</th>
<th>NQS Domain</th>
<th>Measure Source</th>
<th>Reporting Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-Reported Experience</td>
<td>OCM-6</td>
<td>Person and Caregiver-Centered Experience and Outcomes</td>
<td>Survey</td>
<td>CMS-Acquired Data</td>
</tr>
</tbody>
</table>
PRACTICE-REPORTED MEASURES

Practice-reported measures are required to be reported by the OCM Participant to the OCM registry.

Practice-reported measures are aligned to measure specifications used in other CMS programs

- Measures are generally aligned to electronic Clinical Quality Measures (eCQMs) when available and feasible, to support electronic submission of data in an effort to reduce provider burden.

- Additional OCM measures are generally aligned to PQRS measure specifications when eCQMs are not available or feasible, and NQF specifications for measures not utilized in PQRS.

- In order to align to OCM requirements and criteria, OCM specific measures specifications are provided to identify the detailed implementation of the practice-reported measures for the model.

OCM Participants are required to report all practice-reported measures data as required for each measure for each reporting period, each of which is a calendar quarter.
## PRACTICE-REPORTED MEASURES – CONTINUED

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>OCM Measure Number</th>
<th>NQS Domain</th>
<th>Measure Source</th>
<th>Reporting Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology: Medical and Radiation – Pain Intensity Quantified</strong> (NQF 0384/PQRS 143)</td>
<td>OCM-4a</td>
<td>Person and Caregiver-Centered Experience and Outcomes</td>
<td>Registry (practice-reported)</td>
<td>Beneficiary Level - Payment</td>
</tr>
<tr>
<td><strong>Oncology: Medical and Radiation – Plan of Care for Pain</strong> (NQF 0383/PQRS 144)</td>
<td>OCM-4b</td>
<td>Person and Caregiver-Centered Experience and Outcomes</td>
<td>Registry (practice-reported)</td>
<td>Beneficiary Level – Payment</td>
</tr>
<tr>
<td><strong>Preventive Care and Screening: Screening for Depression and Follow-Up Plan</strong> (NQF 0418/ eCQM CMS2.6.3)</td>
<td>OCM-5</td>
<td>Person and Caregiver-Centered Experience and Outcomes</td>
<td>Registry (practice-reported)</td>
<td>Beneficiary Level - Payment</td>
</tr>
<tr>
<td><strong>Prostate Cancer: Adjuvant Hormonal Therapy for High or Very High Risk Prostate Cancer</strong> (NQF 0390/PQRS 104)</td>
<td>OCM-7</td>
<td>Clinical Quality of Care</td>
<td>Registry (practice-reported)</td>
<td>Aggregate Level – Payment; Beneficiary Level - Monitoring</td>
</tr>
<tr>
<td>Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer (NQF 0223)</td>
<td>OCM-8</td>
<td>Clinical Quality of Care</td>
<td>Registry (practice-reported)</td>
<td>Aggregate Level – Payment; Beneficiary Level - Monitoring</td>
</tr>
<tr>
<td>Measure Name</td>
<td>OCM Measure Number</td>
<td>NQS Domain</td>
<td>Measure Source</td>
<td>Reporting Requirement</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------</td>
<td>------------</td>
<td>----------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB - III hormone receptor negative breast cancer (NQF 0559)</td>
<td>OCM-9</td>
<td>Clinical Quality of Care</td>
<td>Registry (practice-reported)</td>
<td>Aggregate Level – Payment; Beneficiary Level - Monitoring</td>
</tr>
<tr>
<td>HER2 targeted therapies received by patients with AJCC stage I (T1c) – IV and HER2 positive breast cancer receiving adjuvant chemotherapy (NQF 1858)</td>
<td>OCM-10</td>
<td>Clinical Quality of Care</td>
<td>Registry (practice-reported)</td>
<td>Aggregate Level – Payment; Beneficiary Level - Monitoring</td>
</tr>
<tr>
<td>Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer (NQF 0387/eCQM CMS140v5.0)</td>
<td>OCM-11</td>
<td>Clinical Quality of Care</td>
<td>Registry (practice-reported)</td>
<td>Aggregate Level – Payment; Beneficiary Level - Monitoring</td>
</tr>
<tr>
<td>Documentation of Current Medications in the Medical Record (NQF 0419/eCQM CMS68v6.1)</td>
<td>OCM-12</td>
<td>Patient Safety</td>
<td>Registry (practice-reported)</td>
<td>Aggregate Level – Payment; Beneficiary Level - Monitoring</td>
</tr>
</tbody>
</table>
QUALITY MEASUREMENT: DATA REGISTRY

• Biological and molecular characteristics of neoplasms relevant to cost and outcome
• Date of progression/relapse
• Date of death*
• Quality measures
• Combination of automated data export and some manual entry
In the first two performance periods there will be a mix of pay-for-reporting (P4R) and pay-for-performance (P4P) measures.

Generally, each measure will have a maximum of 10 points available; the exception is in the first two performance periods, when the P4R measures will have a maximum of 2.5 points available for each.

All earned points will be summed and divided by the practice’s or pool’s total possible points to calculate the aggregate quality score (AQS). The AQS will map to a performance multiplier, which will affect the performance-based payment.

### Aggregate Quality Score Translated into Performance Multiplier

<table>
<thead>
<tr>
<th>Aggregate Quality Score</th>
<th>Performance Multiplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>75% - 100%</td>
<td>100%</td>
</tr>
<tr>
<td>50% - 74%</td>
<td>75%</td>
</tr>
<tr>
<td>30% - 49%</td>
<td>50%</td>
</tr>
<tr>
<td>Below 30%</td>
<td>0%</td>
</tr>
</tbody>
</table>
OCM Payment
TWO PRONGED PAYMENT APPROACH

FFS payments continue as usual to participating practices

1. Monthly Enhanced Oncology Services (MEOS) payment: $160
2. Semi-annual potential for performance-based payment for savings on total cost of care compared to a risk-adjusted target amount

(One-sided risk and two-sided risk arrangements available)
MEOS PAYMENT

• Monthly $160 payment for enhanced services for Medicare FFS beneficiaries with cancer who receive chemotherapy
  • Enhanced services include: 24/7 clinician access, patient navigation, care planning, and use of clinical guidelines
• OCM practices are eligible to bill the MEOS for each month of the 6-month episode, unless the beneficiary enters hospice or dies
• MEOS payments will be included in the practice’s total cost of care for the purposes of calculating the performance-based payment
• MEOS payment amount estimated based on estimated time associated with requested practice redesign activities and staff salaries
Performance Period

- Six-month performance periods

Risk Arrangement Options

- One-sided: Medicare discount = 4%
  - OCM practices are NOT responsible for Medicare expenditures that exceed the target price
  - Must qualify for performance-based payment by mid-2019 to remain in one-sided risk

- Two-sided: Medicare discount = 2.75%
  - OCM practices are responsible for Medicare expenditures that exceed target price
  - Option to take two-sided risk begins in 2017

- Practices must either elect two-sided risk or achieve a performance-based payment by initial reconciliation of the fourth performance period to stay in the model.

Performance-Based Payment (PBP)

- Most cancers eligible for PBP; those that are not are MEOS-only
- PBP based on difference between target amount versus actual episode expenditures
TO CALCULATE THE PERFORMANCE-BASED PAYMENT:

1. Identify baseline episodes
2. Calculate baseline expenditures
3. Calculate the risk-adjusted target amount
4. Identify performance period episodes
5. Calculate actual episode expenditures
6. Calculate the performance multiplier
7. Calculate the performance-based payment
1. IDENTIFY BASELINE EPISODES

- Step 1: Identify episodes
  - Identify potential trigger events
  - Determine episode eligibility
  - Assign cancer type

- Step 2: Attribute episodes to practices
2. CALCULATE BASELINE EPISODE EXPENDITURES

- Medicare Part A Expenditures
- Medicare Part B Expenditures
- Medicare Part D Expenditures (LICS + 80% GDCA)

Baseline Episode Expenditures
3. CALCULATE THE RISK-ADJUSTED TARGET AMOUNT

- Step 3A: Calculate the baseline price
- Step 3B: Calculate the benchmark price
- Step 3C: Calculate the target price
- Step 3D: Calculate the risk-adjusted target amount
For each performance period, episodes will be identified and attributed to practices in the same way as for the baseline period, as previously described.

Recall that these were the steps involved:

1. **Step 1: Identify episodes**
   - Step 1A: Identify potential trigger events
   - Step 1B: Determine episode eligibility
   - Step 1C: Assign cancer type
2. **Step 2: Attribute episodes to practices**
5. CALCULATE ACTUAL EPISODE EXPENDITURES

- Medicare Part A Expenditures
- Medicare Part B Expenditures
- Medicare Part D Expenditures (LICS + 80% GDCA)
- OCM MEOS Payments

Actual Episode Expenditures
6. CALCULATE THE PERFORMANCE MULTIPLIER

• The performance multiplier will be based on the AQS constructed from each practice’s or pool’s performance on the quality measures, as shown here

<table>
<thead>
<tr>
<th>Aggregate Quality Score</th>
<th>Performance Multiplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>75% - 100%</td>
<td>100%</td>
</tr>
<tr>
<td>50% - 74%</td>
<td>75%</td>
</tr>
<tr>
<td>30% - 49%</td>
<td>50%</td>
</tr>
<tr>
<td>Below 30%</td>
<td>0%</td>
</tr>
</tbody>
</table>

• The AQS equals the sum of the points earned on all 12 measures divided by the maximum number of points available.
7. CALCULATE THE PERFORMANCE-BASED PAYMENT

• **If actual episode expenditures are lower than the target amount**: The practice may be paid the full difference (up to a stop gain amount), contingent on quality performance.

• **If actual episode expenditures are higher than the target amount**: No PBP will be made.
  
  • If the practice has elected the two-sided risk sharing arrangement for the performance period, the practice must pay CMS back the difference (up to a stop loss amount), reduced for sequestration.
In order to receive a performance-based payment, a practice or pool must meet the following requirements:

- Actual episode expenditures for the practice/pool must be lower than the target amount for the performance period.
- The practice/pool must have submitted the required data to the OCM data registry.
- The practice, or, in the case of a pool, each practice in the pool, implements all of the Practice Redesign Activities.
- The practice/pool must have achieved a minimum Aggregate Quality Score (AQS) of 30% (out of 100%).
• Potential adjustment to reflect situations where a practice has a higher proportion of expenditures for the use of newly FDA-approved oncology drugs than what is reflected in the trended baseline prices.
  – Includes oncology drugs that received FDA approval after December 31, 2014
  – Use of the novel therapy must be consistent with the FDA-approved indications for inclusion in the adjustment
  – Oncology drugs are considered “new” for 2 years from FDA approval for that specific indication
• The novel therapies adjustment may lead to a higher benchmark only (i.e., it will never lower a benchmark)
• In the future, CMS may modify this adjustment to incorporate value of the novel therapies
Monitoring/Evaluation/Learning
MONITORING AND EVALUATION: OCM-FFS

Participant monitoring activities may include:

- Tracking of claims data
- Patient surveys
- Site visits
- Analysis of quality measurement data
- Time and motion studies
- Medical record audits, tracking of patient complications, and appeals

OCM will employ a non-randomized research design using matched comparison groups to detect changes in utilization, costs, and quality that can be attributed to the model.
The OCM Learning System will provide:

• Topic-specific webinars that allow OCM participants to learn from each other
• An online portal to support learning through shared resources, tools, ideas, discussions, and data-driven approaches to care
• Action Groups in which practices work together to virtually explore critical topics areas and build capability to deliver comprehensive oncology care
• Site visits to better understand how practices manage services, use evidence-based care, and practice patient-centered care
• Coaching to help practices overcome barriers to improvement
CONTACT INFORMATION

Oncology Care Model
CMMI Patient Care Models Group

OCMSupport@cms.hhs.gov
http://innovation.cms.gov/initiatives/Oncology-Care/
Appendix
CANCER BUNDLES

• 21 Cancer Bundles (defined by qualifying ICD-10 code) that are “reconciliation eligible” meaning that performance based payments will be calculated for those cancer types

• Include approximately 95% of cancer cases

• Remaining 5% are not “reconciliation eligible” but MEOS payments can be billed
CANCER TYPE BUNDLES

Caner Bundles

• Acute Leukemia
• Anal Cancer
• Bladder Cancer
• Breast Cancer
• Chronic Leukemia
• CNS Tumor
• Endocrine Tumor
• Female GU other than Ovarian
• Gastro-esophageal Cancer
• Head and Neck Cancer
• Intestinal Cancer
• Kidney Cancer
• Liver Cancer
• Lung Cancer
• Lymphoma
• Malignant Melanoma
• MDS
• Multiple Myeloma
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
Table 1: OCM Prediction Model Variables Variable Name

<table>
<thead>
<tr>
<th>Variable Name</th>
<th>Description (if value=1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEMALE_AGE_18_64</td>
<td>Female, age 18 to 64</td>
</tr>
<tr>
<td>FEMALE_AGE_65_69</td>
<td>Female, age 65 to 69 (reference group)</td>
</tr>
<tr>
<td>FEMALE_AGE_70_74</td>
<td>Female, age 70 to 74</td>
</tr>
<tr>
<td>FEMALE_AGE_75_79</td>
<td>Female, age 75 to 79</td>
</tr>
<tr>
<td>FEMALE_AGE_80+</td>
<td>Female, age 80 or greater</td>
</tr>
<tr>
<td>MALE_AGE_18_64</td>
<td>Male, age 18 to 64</td>
</tr>
<tr>
<td>MALE_AGE_65_69</td>
<td>Male, age 65 to 69</td>
</tr>
<tr>
<td>MALE_AGE_70_74</td>
<td>Male, age 70 to 74</td>
</tr>
<tr>
<td>MALE_AGE_75_79</td>
<td>Male, age 75 to 79</td>
</tr>
<tr>
<td>MALE_AGE_80+</td>
<td>Male, age 80 or greater</td>
</tr>
<tr>
<td>BREAST_PART_D_ONLY_WITH_SURGERY</td>
<td>Breast cancer, only part D chemotherapy drugs, with surgery</td>
</tr>
<tr>
<td>BREAST_PART_D_ONLY_WITHOUT_SURGERY</td>
<td>Breast cancer, only part D chemotherapy drugs, without surgery (reference group)</td>
</tr>
<tr>
<td>BREAST_PART_B_WITH_SURGERY</td>
<td>Breast cancer, at least some Part B chemotherapy drugs, with surgery</td>
</tr>
<tr>
<td>BREAST_PART_B_WITHOUT_SURGERY</td>
<td>Breast cancer, at least some Part B chemotherapy drugs, without surgery</td>
</tr>
<tr>
<td>ANAL_WITH_SURGERY</td>
<td>Anal cancer, with surgery</td>
</tr>
<tr>
<td>ANAL_WITHOUT_SURGERY</td>
<td>Anal cancer, without surgery</td>
</tr>
<tr>
<td>BLADDER_WITH_SURGERY</td>
<td>Bladder cancer, with surgery</td>
</tr>
<tr>
<td>BLADDER_WITHOUT_SURGERY</td>
<td>Bladder cancer without surgery</td>
</tr>
<tr>
<td>FEMALE_GU_WITH_SURGERY</td>
<td>Female GU cancer other than ovary, with surgery</td>
</tr>
<tr>
<td>FEMALE_GU_WITHOUT_SURGERY</td>
<td>Female GU cancer other than ovary, without surgery</td>
</tr>
<tr>
<td>GASTRO_WITH_SURGERY</td>
<td>Gastro/Esophageal cancer, with surgery</td>
</tr>
<tr>
<td>GASTRO_WITHOUT_SURGERY</td>
<td>Gastro/Esophageal cancer, without surgery</td>
</tr>
<tr>
<td>HEAD_NECK_WITH_SURGERY</td>
<td>Head and neck cancer, with surgery</td>
</tr>
<tr>
<td>HEAD_NECK_WITHOUT_SURGERY</td>
<td>Head and neck cancer, without surgery</td>
</tr>
<tr>
<td>INTESTINAL_WITH_SURGERY</td>
<td>Intestinal cancer, with surgery</td>
</tr>
<tr>
<td>INTESTINAL_WITHOUT_SURGERY</td>
<td>Intestinal cancer, without surgery</td>
</tr>
<tr>
<td>LIVER_WITH_SURGERY</td>
<td>Liver cancer, with surgery</td>
</tr>
<tr>
<td>LIVER_WITHOUT_SURGERY</td>
<td>Liver cancer, without surgery</td>
</tr>
</tbody>
</table>
### Table 1: OCM Prediction Model Variables

<table>
<thead>
<tr>
<th>Variable Name</th>
<th>Description (if value=1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNG_WITH_SURGERY</td>
<td>Lung cancer, with surgery</td>
</tr>
<tr>
<td>LUNG_WITHOUT_SURGERY</td>
<td>Lung cancer, without surgery</td>
</tr>
<tr>
<td>OVARY_WITH_SURGERY</td>
<td>Ovarian cancer, with surgery</td>
</tr>
<tr>
<td>OVARY_WITHOUT_SURGERY</td>
<td>Ovarian cancer, without surgery</td>
</tr>
<tr>
<td>PANCREAS_WITH_SURGERY</td>
<td>Pancreatic cancer, with surgery</td>
</tr>
<tr>
<td>PANCREAS_WITHOUT_SURGERY</td>
<td>Pancreatic cancer, without surgery</td>
</tr>
<tr>
<td>PROSTATE_WITH_SURGERY</td>
<td>Prostate cancer, with surgery</td>
</tr>
<tr>
<td>PROSTATE_WITHOUT_SURGERY</td>
<td>Prostate cancer, without surgery</td>
</tr>
<tr>
<td>ACUTE_LEUKEMIA</td>
<td>Acute leukemia</td>
</tr>
<tr>
<td>CHRONIC_LEUKEMIA</td>
<td>Chronic leukemia</td>
</tr>
<tr>
<td>CNS</td>
<td>CNS tumor</td>
</tr>
<tr>
<td>ENDOCRINE</td>
<td>Endocrine tumor</td>
</tr>
<tr>
<td>KIDNEY</td>
<td>Kidney cancer</td>
</tr>
<tr>
<td>LYMPHOMA</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>MDS</td>
<td>Myelodysplastic Syndrome</td>
</tr>
<tr>
<td>MELANOMA</td>
<td>Malignant melanoma</td>
</tr>
<tr>
<td>MYELOMA</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>FULL_DUAL</td>
<td>Enrolled in Part D, full dual, LIS</td>
</tr>
<tr>
<td>PART_D_LIS</td>
<td>Enrolled in Part D, partial dual or LIS applicant, LIS</td>
</tr>
<tr>
<td>PART_D_NO_LIS</td>
<td>Enrolled in Part D, no LIS</td>
</tr>
<tr>
<td>NO_PART_D</td>
<td>Not enrolled in Part D (reference group)</td>
</tr>
<tr>
<td>RADIATION</td>
<td>Received radiation therapy during episode</td>
</tr>
<tr>
<td>BMT_ALLOGENEIC</td>
<td>Received allogeneic BMT during episode</td>
</tr>
<tr>
<td>BMT_AUTOLOGOUS</td>
<td>Received autologous BMT during episode</td>
</tr>
<tr>
<td>CLINICAL_TRIAL</td>
<td>Participated in a clinical trial for cancer during episode</td>
</tr>
<tr>
<td>Variable Name</td>
<td>Description (if value=1)</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>HCC_0</td>
<td>No HCC flags turned on (reference group)</td>
</tr>
<tr>
<td>HCC_1</td>
<td>One HCC flag turned on</td>
</tr>
<tr>
<td>HCC_2</td>
<td>Two HCC flags turned on</td>
</tr>
<tr>
<td>HCC_3</td>
<td>Three HCC flags turned on</td>
</tr>
<tr>
<td>HCC4_5</td>
<td>Four or five HCC flags turned on</td>
</tr>
<tr>
<td>HCC6_OR_MORE</td>
<td>Six or more HCC flags turned on</td>
</tr>
<tr>
<td>New enrollee</td>
<td>New Medicare enrollee (no HCC flags turned on)</td>
</tr>
<tr>
<td>CLEAN_1_61</td>
<td>Clean period between 1 and 61 days</td>
</tr>
<tr>
<td>CLEAN_62_730</td>
<td>Clean period between 62 and 730 days</td>
</tr>
<tr>
<td>CLEAN_731+</td>
<td>Clean period over 730 days or no prior chemo claims (reference group)</td>
</tr>
<tr>
<td>INSTITUTIONAL_STATUS</td>
<td>Was institutionalized for more than 90 days as of the month the episode began</td>
</tr>
<tr>
<td>EP_182_183</td>
<td>Episode length 182 – 183 days</td>
</tr>
<tr>
<td>HRR_RELATIVE_COST</td>
<td>Episode expenditures in beneficiary’s HRR relative to average episode expenditures in all HRRs</td>
</tr>
</tbody>
</table>